All In Biotech

Investigational drug · Phase 3

Pelacarsen

Also called: TQJ230

Not approved by FDA. In 7 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Cardiovascular Disease and Lipoprotein(a), Atherosclerotic Cardiovascular Disease (ASCVD), Atherosclerotic Cardiovascular Disease.

Phase 3

Last checked: Nov 19, 2026Latest source record: Oct 14, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

7

4 still active

All registered trials

14

Any phase or sponsor naming "Pelacarsen"

First trial start

2019

Dec 12, 2019

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Pelacarsen", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Cardiovascular Disease and Lipoprotein(a)
  • Atherosclerotic Cardiovascular Disease (ASCVD)
  • Atherosclerotic Cardiovascular Disease
  • Aortic Stenosis
  • Hyperlipoproteinemia(a)
  • Elevated Lp(a) and Established Atherosclerotic Cardiovascular Disease

Approved drugs for the same conditions: Cardiovascular and metabolic

Largest trials

Live from ClinicalTrials.gov: studies naming "Pelacarsen" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 105 on PubMed

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Novartis.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.